Linfoma diffuso - Diabete - Osteoporosi

from Salute e Società · host Marco Caracciolo

1. Linfoma diffuso a cellule B, AIFA raccomanda la rimborsabilità di tafasitamab sulla base dei risultati dello studio L-MIND che ha mostrato una sopravvivenza globale mediana di 33,5 mesi. 2. FederDiabete Lazio ha avviato un processo di valutazione dei servizi erogati dalla regione, coinvolgendo diabetologi, medici di famiglia, pediatri e pazienti. 3. Un farmaco nuovo e innovativo per la riduzione del rischio di frattura in chi ha l’osteoporosi.

Episode metadata supplied by the publisher feed · Published Dec 5, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Linfoma diffuso - Diabete - Osteoporosi

0:00 6:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Salute e Società?

This episode is 6 minutes long.

When was this Salute e Società episode published?

This episode was published on December 5, 2022.

Can I download this Salute e Società episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!